. Author manuscript; available in PMC: 2009 Nov 1.

Published in final edited form as: Cancer Invest. 2008 Nov;26(9):956–963. doi: 10.1080/07357900802132550

Table 3.

Comparison of results of MOSAIC and NSABP C-07

	MOSAIC		NSABP C-07^b

	FOLFOX	FL	FLOX	FULV

DFS at 3 years, % (95% CI)	78.2^a (75.6, 80.7)	72.9^a (70.2, 75.7)	76.1 (73.6, 78.5)	71.8 (69.2, 74.4)

Absolute improvement in DFS at 3 yrs (95% CI)	5.3%^c (0.0, 10.6)		4.3% (−0.8, 9.3)

Hazard Ratio (95% CI) (reduction in hazard, %)	0.77 (0.65, 0.92)^d(23%) ^a		0.80 (0.69, 0.93) (20%)

p-value	0.002 ^a		0.0034

Median cumulative dose received
5-FU	21759mg/m²	24000mg/m²	7003mg/m²	7800mg/m²

Oxaliplatin	894 mg/m²	NA	676 mg/m²	NA

André, T et al. N Eng J Med. 2004, 350:2343–2351.

Kuebler, JP et al. J Clin Oncol. 2007, 25:2198–2204.

de Gramont A, et al. ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005, (Abstr 3501).

de Gramont A, et al. Proc Am Soc Clin Oncol 22:2003, (Abstr 1015).